<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00314626</url>
  </required_header>
  <id_info>
    <org_study_id>ELA</org_study_id>
    <secondary_id>2004-001198-25</secondary_id>
    <nct_id>NCT00314626</nct_id>
  </id_info>
  <brief_title>Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily</brief_title>
  <official_title>Multicentre, Open Label, Prospective, Randomised Clinical Trial of an Antiretroviral Simplification Treatment With Efavirenz + Abacavir + 3TC Once Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundacio Lluita Contra la SIDA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Germans Trias i Pujol Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the proportion of patients with virological failure after 48 weeks of treatment
      with the combination of efavirenz 600 mg + lamivudine (3TC) 300 mg + abacavir 600 mg once
      daily as an antiretroviral simplification regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment simplification is a therapeutic strategy that allows patients with controlled viral
      replication to switch to an easier-to-take antiretroviral system to promote long-term
      adherence and thus maintain controlled viral load for longer, delaying the evolution of the
      HIV infection.

      The combination of ABC+3TC+EFV is a potent and easy-to-take regimen (2 tablets once a day)
      that could be suitable for the simplification of antiretroviral treatment in patients with
      controlled viral load with a regimen that includes 2 NRTI taken twice daily.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Viral load of HIV-1 at each visit with regard to the baseline visit.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate immunological efficacy (changes in the CD4 and CD8 counts) of the combination studied over the follow-up period.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the tolerance and safety of the combination of abacavir+ lamivudine (in a single tablet) + efavirenz given once daily over 48-week treatment period.</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate treatment adherence (assessed by a self-reported questionnaire and with graduated satisfaction scales) and patient quality of life (assessed by means of the MOS-HIV questionnaire).</measure>
    <time_frame>At 12, 24, 36 and 48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>abacavir 600 mg + lamivudine (3TC) 300 mg in 1 tablet + efavirenz 600 mg 1/24h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>efavirenz + 2 NUCS</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>efavirenz</intervention_name>
    <description>Efavirenz</description>
    <arm_group_label>A</arm_group_label>
    <other_name>sustiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir+lamivudine</intervention_name>
    <description>Abacavir+lamivudine</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Kivexa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years.

          2. HIV-1 infected patients.

          3. Patients on HAART therapy including efavirenz and two NRTIs in a twice-daily regimen
             for 6 months at least.

          4. Patients with an undetectable HIV-1 viral load over the last 6 months (at least 2
             determinations separated by 3 months).

          5. Subject able to follow the treatment period.

          6. Signature of the informed consent.

          7. Women may not be of fertile age (defined as at least one year from menopause or
             undergoing any surgical sterilisation technique), or must undertake to use a barrier
             contraceptive method during the study.

        Exclusion Criteria:

          1. Hepatic tests &gt; 5 times above normality.

          2. Pregnancy or breastfeeding

          3. Presence of opportunistic infections and/or recent tumours (&lt; 6 months).

          4. Suspected or documented resistance to any of the investigational drugs.

          5. Known allergic hypersensitivity to any of the investigational drugs or any similar
             drug.

          6. Subjects with abusive consumption of alcohol or illegal drugs.

          7. Patients participating in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bonaventura Clotet, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lluita contra la Sida Foundation-HIV Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Germans Trias i Pujol Hospital</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró</name>
      <address>
        <city>Mataro</city>
        <state>Barcelona</state>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Aranzazu</name>
      <address>
        <city>San Sebastian</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Millan de Logroño</name>
      <address>
        <city>Logroño</city>
        <state>La Rioja</state>
        <zip>26001</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcala de Henares</city>
        <state>Madrid</state>
        <zip>28005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Móstoles</name>
      <address>
        <city>Mostoles</city>
        <state>Madrid</state>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Santa Cruz de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Severo Ochoa Leganés</name>
      <address>
        <city>Madrid</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Cristal-Piñor</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Santa María Nai</name>
      <address>
        <city>Ourense</city>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2006</study_first_submitted>
  <study_first_submitted_qc>April 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2006</study_first_posted>
  <last_update_submitted>January 25, 2008</last_update_submitted>
  <last_update_submitted_qc>January 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>LLuita Sida Foundation</name_title>
    <organization>LLuita Sida Foundation</organization>
  </responsible_party>
  <keyword>Antiviral efficacy</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Immunologic response</keyword>
  <keyword>Virologic response</keyword>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Dideoxynucleosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

